Several studies have shown that upregulation of ts-MHC-II, which is typically associated with increased numbers of CD4+ and CD8+ tumor-infiltrating lymphocytes, leads to tumor rejection and improves the immunotherapy response [25,39,43,45]. This evidence concerns the gene CD8A and neoplasm.